Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized trial of crenolanib versus midostaurin after induction and consolidation therapy in newly diagnosed FLT3-mutated acute myeloid leukemia
MOH_2019-02-24_004907Phase 3Completed
- Sponsor
- AROG Pharmaceuticals, Inc.
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of crenolanib and midostaurin in acute myeloid leukemia (AML) (2 arms), sponsored by AROG Pharmaceuticals, Inc. Primary endpoint: Event-free survival. Started Jan 2019; status: completed.
02
Drugs
crenolanibmidostaurin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on MOH_2019-02-24_004907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-02-24_004907.